FAPI-46 (68Ga)

DRUG2 trials

Sponsors

GE Healthcare Limited, Centre Hospitalier Universitaire De Nantes

Conditions

ColorectalGastricOvarian or Pancreatic CancerTransthyretin cardiac amyloidosis

Phase 2

A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients with Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Not yet recruitingCTIS2024-519384-18-00

GE Healthcare LimitedColorectal, Gastric, Ovarian or Pancreatic Cancer

Target: 5Updated: 2026-02-25

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

Not yet recruitingCTIS2025-523616-36-00

Centre Hospitalier Universitaire De NantesTransthyretin cardiac amyloidosis

Target: 40Updated: 2026-06-13